Durvalumab + Cisplatin + Carboplatin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Cervical Cancer
Conditions
Locally Advanced Cervical Cancer
Trial Timeline
Feb 15, 2019 → Jul 3, 2023
NCT ID
NCT03830866About Durvalumab + Cisplatin + Carboplatin
Durvalumab + Cisplatin + Carboplatin is a phase 3 stage product being developed by AstraZeneca for Locally Advanced Cervical Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03830866. Target conditions include Locally Advanced Cervical Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced Cervical Cancer were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03830866 | Phase 3 | Completed |
Competing Products
20 competing products in Locally Advanced Cervical Cancer